Literature DB >> 21865786

Polymethylmethacrylate membrane with a series of serendipity.

Yoshitada Sakai1.   

Abstract

Forty years have passed since the polymethylmethacrylate (PMMA) membrane was first developed. This article reviews its history and explains its longevity. The membrane was developed through application of a stereocomplex phenomenon that is observed upon mixture of isotactic and syndiotactic PMMA polymers. Filtryzer(TM) B1 and B2 were approved in Japan in 1977. B1 was the pioneer high-performance membrane model and B2 was a model that simulated a low-flux cellulosic membrane. The development of B1 led to the development of the dialysis machine with an ultrafiltration rate (UFR)-controlling function because the UFR of B1 was too high to control using transmembrane pressure control. B1 was used not only as a dialyzer but also as a hemodiafilter by combination with a UFR controller. Biocompatibility of the dialysis membrane, complement activation and/or transient leukopenia was studied with B2. Cooperative studies between Niigata University and Toray resulted in Gejyo's finding regarding the harmfulness of β(2)-microglobulin (BMG). Long-term follow-up of patients dialyzed using the BK membrane revealed that plasma BMG levels were significantly low and that the occurrence ratio of carpal tunnel syndrome was suppressed. These results were obtained by the adsorptive removal of BMG onto a PMMA membrane. Several papers have discussed new aspects in succession mainly based on clinical experiences that were not aimed at a development stage, i.e. they were kinds of serendipity. For the BK-F membrane with the largest pore size, this includes anemia and removal or modification of furancarboxylic acid, homocysteine, pentosidine and soluble CD40. For the BG membrane with a slightly anionic component, this includes pruritus and removal of free immunoglobulin light chains. Even patients' prognoses may be modified by the use of PMMA membrane. The mechanisms of these findings have been clarified bit by bit and the membrane will further open new frontiers in dialysis treatment.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865786     DOI: 10.1159/000329052

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  2 in total

1.  Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013.

Authors:  Toshiaki Arimura; Masanori Abe; Hidetoshi Shiga; Hiroshi Katayama; Kazo Kaizu; Shigeto Oda
Journal:  J Artif Organs       Date:  2017-06-09       Impact factor: 1.731

2.  Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: Results from the annual survey of the Japanese Nationwide Dialysis Registry.

Authors:  Masanori Abe; Takayuki Hamano; Atsushi Wada; Shigeru Nakai; Ikuto Masakane
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.